Article Text

Download PDFPDF
Research priority setting by young people with rheumatic musculoskeletal disease
  1. Janet E McDonagh1,
  2. Laura Lunt2,
  3. Katharine Cresswell3,
  4. Suzanne Parsons3,
  5. Rachel Tattersall4
  6. on behalf of Barbara Ansell National Network for Adolescent Rheumatology BANNAR
  1. 1 Centre for MSK Research, University of Manchester, Manchester, UK
  2. 2 University of Manchester, Manchester, UK
  3. 3 Manchester University Hospitals NHS Trust, Manchester, UK
  4. 4 Sheffield Children’s Hospital, Sheffield, UK
  1. Correspondence to Dr Janet E McDonagh, Centre for MSK Research, University of Manchester, Manchester M13 9PT, UK; janet.mcdonagh{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We would like to commend the timely review by Dr Odgers and colleagues,1 highlighting the lack of child/caregiver involvement and the need for greater clarity in methodology in studies, eliciting stakeholder priorities for paediatric chronic disease research. As the period of study ended in October 2016, we would like to provide an update on our own work in this area published since this date and briefly mentioned in the discussion.2 3 We involved a relatively large number of young people (n=63, age range 10–24 years, 43 females, 20 males) with a range of chronic rheumatic musculoskeletal disease across all four nations of the UK …

View Full Text


  • Contributors All authors have contributed to the original research, the writing of this letter and approval of the letter. RT and JMcD are chair and deputy chair of BANNAR. LL, KC and SP are involved in facilitating Your Rheum. BANNAR members are involved in the recruitment of YOUR Rheum members.

  • Funding This study was funded by Arthritis Research UK (20164).

  • Competing interests JMcD: receipt of speakers fees and/or support to attend international rheumatology conferences from Pfizer, Abbvie, Sanofi Genzyme and Biomarin.

  • Provenance and peer review Not commissioned; internally peer reviewed.

  • Collaborators BANNAR Barbara Ansell National Network for Rheumatology.